- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Construction Boom
Global Pharmaceuticals & Biotech Construction Boom
UPDATED Mar 06, 2024
Highly cyclical companies in construction-related industries with a strong future outlook.
120 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 300896Imeik Technology DevelopmentLtd | CN¥321.20 | 1.4% | -43.1% | CN¥69.1b | CN¥456.90 | PE40.9x | E31.1% | 1.2% | ||
| MARKSANSMarksans Pharma | ₹147.80 | -3.2% | 115.5% | ₹69.3b | n/a | PE21.2x | E20.6% | 0.3% | ||
| NEUNeuren Pharmaceuticals | AU$19.65 | 2.6% | 150.0% | AU$2.5b | AU$26.74 | PE15.9x | E7.0% | n/a | ||
| 300841Chengdu Kanghua Biological Products | CN¥62.75 | 2.0% | -35.2% | CN¥8.5b | CN¥84.99 | PE17.4x | E20.8% | 0.8% | ||
| GENOGenovis AB (publ.) | kr38.00 | 0.5% | -33.7% | kr2.5b | kr68.00 | PE40.5x | E3.3% | n/a | ||
| ARCTArcturus Therapeutics Holdings | US$37.78 | -6.0% | 131.4% | US$1.0b | US$66.33 | PE10.2x | E45.3% | n/a | ||
| 603392Beijing Wantai Biological Pharmacy Enterprise | CN¥70.95 | 0.06% | -19.9% | CN¥94.0b | CN¥69.43 | PE34.6x | E34.3% | 1.0% | ||
| 6620Handa Pharmaceuticals | NT$190.50 | 11.4% | -3.8% | NT$26.9b | NT$200.00 | PE38x | E78.9% | n/a | ||
| TGTXTG Therapeutics | US$18.23 | 3.4% | 4.4% | US$2.6b | US$29.75 | PE208.3x | E49.9% | n/a | ||
| ACRAcrux | AU$0.055 | -3.5% | -11.3% | AU$16.0m | n/a | PS1.4x | E115.3% | 0% | ||
| TLXTelix Pharmaceuticals | AU$12.00 | -1.1% | 62.6% | AU$3.9b | AU$14.40 | PE746.1x | E37.4% | n/a | ||
| 524735Hikal | ₹277.25 | -1.0% | -10.3% | ₹34.6b | ₹330.00 | PE47.7x | E37.7% | 0.4% | ||
| COPNCosmo Pharmaceuticals | CHF67.40 | 2.3% | 13.1% | CHF1.1b | CHF75.96 | PE104x | E36.9% | 1.5% | ||
| MDPMedexus Pharmaceuticals | CA$1.71 | -5.0% | 2.4% | CA$41.6m | CA$3.25 | PE5.3x | E50.1% | n/a | ||
| XBRANEXbrane Biopharma | kr0.70 | 25.0% | -99.2% | kr20.9m | kr122.00 | PB0.1x | E143.5% | n/a | ||
| GTIIGreen Thumb Industries | CA$16.18 | -5.5% | 40.1% | CA$4.2b | CA$24.50 | PE78.9x | E26.5% | n/a | ||
| SPAGOSpago Nanomedical | kr0.31 | 5.1% | -61.0% | kr70.1m | kr1.48 | PS11.8x | E48.9% | n/a | ||
| 603087Gan & Lee Pharmaceuticals | CN¥41.66 | -0.7% | 14.2% | CN¥24.9b | CN¥57.00 | PE102.1x | E68.1% | 0.7% | ||
| APPHApontis Pharma | €6.22 | 1.0% | -44.7% | €51.8m | €14.67 | PS1.1x | E66.9% | n/a | ||
| MDXGMiMedx Group | US$8.07 | -1.6% | 99.8% | US$1.2b | US$12.52 | PE21.3x | E15.8% | n/a | ||
| AXSMAxsome Therapeutics | US$72.15 | -13.0% | 13.5% | US$3.6b | US$120.53 | PS12.6x | E60.3% | n/a | ||
| CDXCChromaDex | US$1.74 | 1.2% | -4.9% | US$130.3m | US$4.88 | PS1.6x | E111.1% | n/a | ||
| HALOHalozyme Therapeutics | US$41.69 | 5.0% | -1.9% | US$5.3b | US$48.64 | PE18.8x | E19.5% | n/a | ||
| CALTXCalliditas Therapeutics | kr114.30 | 3.1% | 19.8% | kr6.2b | kr208.00 | PS5.1x | E47.8% | n/a |